The program aims to improve growth through continued advancement of Takeda's Growth & Launch Products and progressing the company's robust late-stage pipeline to deliver innovative therapies for patients, while helping drive Core Operating Profit margin improvement target of low- to mid-30%.
The program will start in FY2024 and includes initiatives to optimize its workforce-simplifying some division structures-and rigorously prioritize its R&D pipeline, while investing in DD&T to increase productivity and efficiency across the organization. Procurement-led initiatives will be centered on optimizing external spend with the goal of achieving cost savings and efficiencies in Takeda's supply chain and vendor management processes. Details and timing of specific actions within the framework of these broader initiatives will be decided in due course.
This program underscores Takeda's commitment to driving sustainable growth, operational excellence and financial resilience in the years ahead, while enabling it to create more long-term value for patients, the global health care system and society.
Takeda estimates that efficiencies and savings resulting from the multi-year program, offset by investments in its late-stage pipeline and DD&T, will drive 100-250 basis points of Core Operating Profit margin improvement each year from FY2025 towards its target of low- to mid-30%-with the amount of basis point improvement each year dependent upon various factors, including business environment and foreign exchange rates. Primarily as a result of the initiatives, Takeda estimates it will incur one-time restructuring expenses of
About Takeda
Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in
Contact:
Email: christopher.oreilly@takeda.com
Tel: +81 (0) 3-3278-2543
Email: brendan.jennings@takeda.com
Tel: +81 (0) 80-2705-8259
Forward-Looking Statements
This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda's future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as 'targets', 'plans', 'believes', 'hopes', 'continues', 'expects', 'aims', 'intends', 'ensures', 'will', 'may', 'should', 'would', 'could', 'anticipates', 'estimates', 'projects', 'forecasts', 'outlook' or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda's global business, including general economic conditions in
(C) 2024 Electronic News Publishing, source